Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
Investor's Business Daily on MSN43m
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionRoche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback